Optimize and de-risk your drug candidate’s success at every development stage with our modeling strategy.
From Lead Optimization to registration, PhinC supports you with high-value modeling strategies that turn your data into fast and robust decisions.
Select the best candidates early in development.
Modeling connects molecular properties, expected exposure, and early signals to prioritize options and reduce the risk of advancing a suboptimal candidate.
- Compare candidates and objectively assess selection criteria.
- Anticipate exposure and the therapeutic window from early data.
- Identifier les facteurs limitants (ADME, variabilité) et orienter les choix.
Strengthen translation and de-risk your preclinical package.
We integrate in vitro and in vivo data to reduce key uncertainties and improve human translation prior to clinical entry.
- Optimize species, study designs, and biomarkers to maximize translational relevance.
- Extrapolate exposure and support early justification of doses and routes of administration.
- Assess parameter sensitivity and prioritize the most impactful studies.
Secure first-in-human entry and streamline dose escalation.
Modeling supports FIH, dose-escalation strategy, and variability analysis to enable fast decisions, limit risk, and document defensible choices.
- Define starting dose, escalation steps, and escalation rules on a scientific basis.
- Quantify variability and key covariates (weight, sex, renal and hepatic function).
- Link exposure, tolerability, and PD markers to inform downstream development decisions.
Strengthen proof of concept with a clear dose–exposure–response strategy.
In Phase II, we clarify the dose → exposure → response relationship to select the dose, optimize study design, and reduce uncertainty ahead of Phase III.
- Evaluate study designs (cohorts, regimens, endpoints) to maximize decision-making power.
- Characterize exposure–response relationships for efficacy and safety to support robust dose selection.
- Explore subpopulations quantify variability and identify key covariates to inform a robust Phase III strategy.
Reduce uncertainty and support a scientifically defensible final dose.
Modeling consolidates the dosing regimen, anticipates covariate effects, and secures analyses to avoid surprises and strengthen the robustness of conclusions.
- Confirm the final dose and quantify benefit–risk across relevant subpopulations.
- Optimize analyses and manage unexpected events (adherence, protocol deviations).
- Structure key MIDD deliverables ahead of regulatory interactions.
Strengthen your submission package with pharmacological models
We translate your analyses into quantitative, regulator-ready recommendations: dosing, scenarios, and deliverables aligned with regulatory expectations.
- Consolidate a coherent and defensible dosing strategy and labeling.
- Support DDIs, special populations, and dose adjustments with traceable analyses.
- Produce M&S reports and appendices ready for submission and regulatory interactions.
